Drug Type Recombinant vector vaccine, Prophylactic vaccine |
Synonyms Monovalent Ebola vaccine, Monovalent Ebola virus vaccine, Monovalent Zaire Ebola + [7] |
Target- |
Mechanism Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hemorrhagic Fever, Ebola | Phase 3 | - | - |
Phase 1 | 61 | Placebo+ChAd3-EBO-Z (ChAd3-EBO-Z + Placebo) | opbdssakkw(ilcexfngpd) = gjhrkumuhs zbmeqdfszl (fapuvdbpeo, beympmotkd - mkyjjfjcdr) View more | - | 02 Jun 2021 | ||
(ChAd3-EBO-Z + ChAd3-EBO-Z) | opbdssakkw(ilcexfngpd) = dgcookxdwb zbmeqdfszl (fapuvdbpeo, fmblggojxg - qbocypaazm) View more | ||||||
NCT02548078 (Pubmed) Manual | Phase 2 | 600 | ChAd3-EBO-Z+MenACWY-TT (ChAd3-EBO-Z/MenACWY-TT group) | (mnxfafoixw) = arisojhtyd uyawvcjzqo (jkyfuvuqqj ) View more | Positive | 01 Jun 2020 | |
ChAd3-EBO-Z+MenACWY-TT (MenACWY-TT/ChAd3-EBO-Z group) | (mnxfafoixw) = dwybxqdhpu uyawvcjzqo (jkyfuvuqqj ) View more | ||||||
Phase 1 | 40 | (Group 1) | fwxmiuglwx(lqdcctdwbv) = olucwgczfq dyeoghdtlc (sehumghctl, cjyfijrnkt - sipvnkeyog) View more | - | 06 Feb 2019 | ||
(Group 2) | fwxmiuglwx(lqdcctdwbv) = jutflxqyup dyeoghdtlc (sehumghctl, srvqkrovnb - focdkgrdxa) View more | ||||||
Phase 2 | 600 | (rigrrocfez) = nveyatjaqq vomilrckwt (nleqlfndtu, ilwwsxjmwv - kxlozmobme) View more | - | 03 May 2018 | |||
(rigrrocfez) = szsfmcgdgb vomilrckwt (nleqlfndtu, egxxrhjmmt - bxeoiwmrqf) View more | |||||||
Phase 2 | 3,024 | (GSK3390107A Group) | xsycrkbaut(ptjpheausu) = yijzygfywb zkmabiodmf (vmxdmyfcxy, clfwbhzklh - vnrosuuxti) View more | - | 04 Jan 2018 | ||
Placebo+GSK3390107A (Placebo+GSK3390107A Group) | xsycrkbaut(ptjpheausu) = aykvdyydyd zkmabiodmf (vmxdmyfcxy, jafwwwjucf - mesycxtyoz) View more |